Call Buying Activity in AbbVie (ABBV) Targets 3% Upside in Shares Into Mid-November Ahead Various Drug Trials -Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mail
Get Alerts ABBV Hot Sheet
Price: $284.80 -1.48%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.4%
Revenue Growth %: +10.0%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.4%
Revenue Growth %: +10.0%
Join SI Premium – FREE
Susquehanna option strategist Alison Edwards notes call buying in AbbVie (NYSE: ABBV) ahead of various drug trials, as investors purchased Nov 91 Calls with roughly 7,500 trading for $1.25, targeting 3% upside into mid-Nov.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Allergan Aesthetics presents eight posters at AMWC Dubai
- IBM (IBM) call put ratio 1.1 calls to 1 put into quarter results
- Lockheed Martin (LMT) call put ratio 1 call to 1 put into quarter results
Create E-mail Alert Related Categories
Options, Trader TalkRelated Entities
Susquehanna International Group of CompaniesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
